Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Blood (2024) 144 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2024-203781

Published: 2024

Journal Articles

Patient Experience with Venetoclax+Rituximab and BTK Inhibitors in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL): A Qualitative Interview Study in the UK (ELECTRIC)

Dima el-Sharkawi, Deborah Rahman, Lisa Lowry, Jo Kelly, Hanna Kew, Nimish Shah, Daniel Martins, Toby Kent, Louise Powell, Beenish Manzoor, Nicolas Martinez-Calle

Blood (2024) 144 (Supplement 1): 3731.

https://doi.org/10.1182/blood-2024-209883

Published: 2024

Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J.M. Ferreri, Kate Cwynarski, Pamela McKay

Blood (2022) 139 (16): 2499–2511.

https://doi.org/10.1182/blood.2021014506

Published: 2022

Includes: Supplemental data

Journal Articles

Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Matthew R Wilson, Toby A. Eyre, Amy A Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolas Martinex-Calle, Gavin Preston, Matthew J Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L Lewis, Teresa Calimeri, Eric Durot, Loic Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Tim Ebsworth, Johnathon Elliot, Anna Santarsiere, Laure Ricard, Nimish Shah, Qin Liu, Adam Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish W Scott, Anna Guidetti, Brett R Barlow, Jeffrey Smith, Tarec Christoffer El-Galaly, Chan Yoon Cheah, Andres JM Ferreri, Fiona Miall, Christopher P Fox, Kate Cwynarski, Pamela McKay

Blood (2021) 138 (Supplement 1): 452.

https://doi.org/10.1182/blood-2021-144820

Published: 2021

Journal Articles

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Blood (2021) 138 (Supplement 1): 877.

https://doi.org/10.1182/blood-2021-146242

Published: 2021

Journal Articles

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Stephen Booth, Eliza Hawkes, Amy A Kirkwood, Sally F Barrington, Patrick G. Medd, Pamela McKay, Ruth Pettengell, Sunil Iyengar, Fiona Miall, John Radford, Cathy Burton, Amit Sud, Nimish Shah, Andrew M Scott, Arzhang Ardavan, Michael Northend, Laura Clifton-Hadley, Richard Jenner, Graham P. Collins

Blood (2021) 138 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2021-145189

Published: 2021

Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Blood (2019) 134 (Supplement_1): 3993.

https://doi.org/10.1182/blood-2019-125947

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

Advanced-Stage Hodgkin Lymphoma in the East of England Cancer Network: A 10-Year Comparative Analysis of Outcomes for Patients Treated with ABVD or Escalated BEACOPP in the Non-Trial Setting Compared with Age-Matched Patients Treated in the Multinational RATHL Trial

James Russell, MD, Angela Collins, MD, Alexis Fowler, MD, Mamatha Karanth, MD, Isabel Lentell, MD, Chandan Saha, MD, Suzanne Docherty, MD, Joseph Padayatty, MD, Kyaw Maw, MD, Lisa Cooke, MD, Andrew Hodson, MD, Nimish Shah, MD, Shalal Sadullah, MD, Nicholas Grigoropoulos, MD PhD, Wendi Qian, Amy A Kirkwood, Benjamin J Uttenthal, MD PhD, Peter Johnson, MD FRCP, George A Follows, MD PhD

Blood (2017) 130 (Supplement 1): 735.

https://doi.org/10.1182/blood.V130.Suppl_1.735.735

Published: 2017

Journal Articles

Multicentre Retrospective Analysis of Chronic Lymphocytic Leukaemia Patients Treated with Idelalisib, "Real World" Data from the UK and Republic of Ireland - a Cohort of 68 Patients

Blood (2017) 130 (Supplement 1): 1733.

https://doi.org/10.1182/blood.V130.Suppl_1.1733.1733

Published: 2017

Journal Articles

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles, Martin J. S. Dyer

Blood (2017) 129 (20): 2808–2810.

https://doi.org/10.1182/blood-2017-02-765115

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Blood (2016) 127 (4): 411–419.

https://doi.org/10.1182/blood-2015-08-664086

Published: 2016

Includes: Supplemental data

Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

Blood (2014) 124 (21): 3328.

https://doi.org/10.1182/blood.V124.21.3328.3328

Published: 2014

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 4397.

https://doi.org/10.1182/blood.V122.21.4397.4397

Published: 2013

Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD

Blood (2013) 122 (21): 676.

https://doi.org/10.1182/blood.V122.21.676.676

Published: 2013

NARROW

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Patient Experience with Venetoclax+Rituximab and BTK Inhibitors in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL): A Qualitative Interview Study in the UK (ELECTRIC)

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Advanced-Stage Hodgkin Lymphoma in the East of England Cancer Network: A 10-Year Comparative Analysis of Outcomes for Patients Treated with ABVD or Escalated BEACOPP in the Non-Trial Setting Compared with Age-Matched Patients Treated in the Multinational RATHL Trial

Multicentre Retrospective Analysis of Chronic Lymphocytic Leukaemia Patients Treated with Idelalisib, "Real World" Data from the UK and Republic of Ireland - a Cohort of 68 Patients

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only